Carnegie Capital Asset Management LLC Raises Stock Position in Bristol-Myers Squibb (NYSE:BMY)
Carnegie Capital Asset Management LLC Raises Stock Position in Bristol-Myers Squibb (NYSE:BMY)
Carnegie Capital Asset Management LLC boosted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 0.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 109,550 shares of the biopharmaceutical company's stock after buying an additional 187 shares during the quarter. Carnegie Capital Asset Management LLC's holdings in Bristol-Myers Squibb were worth $7,882,000 as of its most recent SEC filing.
根據該公司最近向證券交易委員會提交的 13F 表格，卡內基資本資產管理有限責任公司在第四季度將其在百時美施貴寶（NYSE：BMY — 獲得評級）的持有量提高了 0.2％。該公司在本季度額外購買 187 股後，擁有該生物製藥公司股票的 109,550 股。卡內基資本資產管理有限責任公司在百時美施貴寶的持股價值 7,882,000 美元作為其最近的 SEC 備案。
Several other institutional investors also recently bought and sold shares of BMY. Dakota Wealth Management acquired a new position in shares of Bristol-Myers Squibb during the 1st quarter worth about $332,000. Covestor Ltd raised its holdings in shares of Bristol-Myers Squibb by 111.5% in the 1st quarter. Covestor Ltd now owns 2,052 shares of the biopharmaceutical company's stock valued at $150,000 after purchasing an additional 1,082 shares in the last quarter. NewEdge Advisors LLC raised its holdings in shares of Bristol-Myers Squibb by 53.2% in the 1st quarter. NewEdge Advisors LLC now owns 165,336 shares of the biopharmaceutical company's stock valued at $12,075,000 after purchasing an additional 57,444 shares in the last quarter. Ergoteles LLC acquired a new stake in Bristol-Myers Squibb during the 1st quarter worth $1,997,000. Finally, Mackenzie Financial Corp raised its stake in Bristol-Myers Squibb by 25.1% during the 1st quarter. Mackenzie Financial Corp now owns 338,563 shares of the biopharmaceutical company's stock worth $24,725,000 after acquiring an additional 68,018 shares in the last quarter. 75.51% of the stock is currently owned by institutional investors and hedge funds.
其他幾家機構投資者最近還買賣了 BMY 的股票。達科他州財富管理收購了百時美施貴寶股份的新位置在第一季度價值約 $332,000.科維斯特有限公司於第一季增加其對百時美施貴寶股份的持有量達 111.5%。科維斯特有限公司現在擁有該生物製藥公司的 2,052 股股份，價值為 15 萬美元，在上一季度額外購買 1,082 股股份後。新際顧問有限責任公司在第一季度上升了百時美施貴寶股份的持有量 53.2%。新際顧問公司現在擁有 165,336 股價值 12,075,000 美元的生物製藥公司股票，在上一季度額外購買 57,444 股股票後。麥角力有限責任公司在第一季度價值 1,997,000 美元期間收購了百時美施貴寶的新股份。最後，麥肯齊金融公司在第一季度上調了 25.1％ 在百時邁施貴寶的股份。麥肯齊金融公司現在擁有該生物製藥公司股票的 338,563 股，價值 24,725,000 美元，在上個季度額外收購 68,018 股股票。75.51％ 的股票目前由機構投資者和對沖基金擁有。
Bristol-Myers Squibb Trading Up 1.1 %
百時美施貴寶交易上升 1.1%
Shares of NYSE BMY traded up $0.78 during trading hours on Friday, reaching $68.98. The stock had a trading volume of 3,850,653 shares, compared to its average volume of 8,100,103. The business's fifty day moving average price is $70.16 and its two-hundred day moving average price is $72.82. The company has a current ratio of 1.25, a quick ratio of 1.14 and a debt-to-equity ratio of 1.13. The firm has a market cap of $145.09 billion, a price-to-earnings ratio of 23.12, a P/E/G ratio of 1.48 and a beta of 0.46. Bristol-Myers Squibb has a 52-week low of $65.28 and a 52-week high of $81.43.
紐約證券交易所的股票在周五交易時間內上漲 0.78 美元，達到 68.98 美元。該股的交易量為 3,850,653 股，與其平均交易量為 8,103 股相比。該企業的五十天移動平均價格為 70.16 美元，其 200 天移動平均價格為 72.82 美元。該公司的流動比率為 1.25，快速比率為 1.14，債務與權益比率為 1.13。該公司的市值為 145.09 億美元，股價與盈利比率為 23.12，盈利率為 1.48，貝塔值為 0.46。百時美施貴寶擁有 52 周低點 65.28 美元和 52 周高點 81.43 美元。
Bristol-Myers Squibb (NYSE:BMY – Get Rating) last released its quarterly earnings data on Thursday, February 2nd. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating analysts' consensus estimates of $1.71 by $0.11. Bristol-Myers Squibb had a return on equity of 51.60% and a net margin of 13.71%. The business had revenue of $11.41 billion during the quarter, compared to analyst estimates of $11.20 billion. During the same quarter last year, the business posted $1.83 EPS. The company's revenue was down 4.8% on a year-over-year basis. Analysts expect that Bristol-Myers Squibb will post 8.06 EPS for the current fiscal year.
百時美施貴寶 (紐約證交所代碼:BMY — 獲得評分) 最後一次公布其季度收益數據，日期為 2 月 2 日（星期四）。這家生物製藥公司報告了本季度每股 1.82 美元的收益，超過了分析師的 1.71 美元的共識估計，達到 0.11 美元。百時美施貴寶的股本回報率為 51.60%，淨利潤率為 13.71%。該業務在本季度的營收為 1141 億美元，而分析師估計為 11.20 億美元。在去年同一季度，該業務每股收益 1.83 美元。該公司的收入較去年同期下降了 4.8%。分析師預計，百時美施貴寶將在本會計年度錄得 8.06 每股盈餘。
Bristol-Myers Squibb Dividend Announcement
百時美施貴寶股息公告
The company also recently announced a quarterly dividend, which will be paid on Monday, May 1st. Shareholders of record on Monday, April 10th will be given a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 3.31%. The ex-dividend date is Thursday, April 6th. Bristol-Myers Squibb's payout ratio is 77.29%.
該公司最近還宣布了季度股息，將於 5 月 1 日（週一）支付。4 月 10 日（星期一）有記錄的股東將獲得 0.57 美元的股息。這代表每年 2.28 美元的股息，收益率為 3.31%。除息日期為 4 月 6 日星期四。百時美施貴寶的支付比率為 77.29%。
Analyst Ratings Changes
分析師等級變更
Several analysts have recently weighed in on the stock. Atlantic Securities lifted their target price on shares of Bristol-Myers Squibb from $88.00 to $90.00 and gave the company an "overweight" rating in a report on Friday, February 3rd. Jefferies Financial Group started coverage on shares of Bristol-Myers Squibb in a research report on Monday, March 6th. They set a "hold" rating and a $62.00 target price for the company. StockNews.com started coverage on shares of Bristol-Myers Squibb in a research report on Thursday, March 16th. They issued a "strong-buy" rating for the company. Wells Fargo & Company upped their target price on shares of Bristol-Myers Squibb from $70.00 to $78.00 and gave the company an "equal weight" rating in a research note on Tuesday, January 3rd. Finally, Cantor Fitzgerald began coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, January 17th. They issued an "overweight" rating and a $95.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $79.69.
幾位分析師最近對股票進行了權衡。大西洋證券將百時美施貴寶股票的目標價格從 88.00 美元提高至 90.00 美元，並在 2 月 3 日（星期五）的一份報告中給予該公司「超重」評級。富瑞金融集團於 3 月 6 日（星期一）在一份研究報告中開始對百時美施貴寶的股份進行報導。他們為該公司設定了「持有」評級和 62.00 美元的目標價格。Stocknews.com 於 3 月 16 日（星期四）在一份研究報告中開始報導百時美施貴寶的股份。他們為公司頒發了「強買」評級。富國銀行公司將百時美施貴寶股份的目標價從 70.00 美元提高至 78.00 美元，並於 1 月 3 日（星期二）的一份研究報告中給予該公司「同等權重」評級。最後, 坎托·菲茨杰拉德開始覆蓋百時邁施貴寶的股份在週二的研究報告, 1 月 17 日.他們為該公司頒布了「超重」評級和 95.00 美元的目標價格。一位投資分析師對該股票進行了賣出評級，七人發出了持有評級，七人發出了買入評級，其中一名給予了強大的買入評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為「中等買入」，共識目標價為 79.69 美元。
Insider Transactions at Bristol-Myers Squibb
百時美施貴寶內幕交易
In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 240,000 shares of the company's stock in a transaction on Monday, February 6th. The shares were sold at an average price of $74.65, for a total value of $17,916,000.00. Following the completion of the transaction, the chief executive officer now owns 236,104 shares in the company, valued at $17,625,163.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Ann Powell sold 11,183 shares of the business's stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $74.69, for a total value of $835,258.27. Following the completion of the sale, the executive vice president now owns 23,043 shares of the company's stock, valued at approximately $1,721,081.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Giovanni Caforio sold 240,000 shares of the business's stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $74.65, for a total transaction of $17,916,000.00. Following the transaction, the chief executive officer now directly owns 236,104 shares of the company's stock, valued at $17,625,163.60. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company's stock.
在其他百時美施貴寶新聞中，首席執行官喬瓦尼·卡福里奧在 2 月 6 日（週一）的一項交易中出售了 24 萬股該公司股票。這些股票以平均價格 74.65 美元出售，總價值為 17,916 萬美元。交易完成後，首席執行官現在擁有該公司的 236,104 股股份，價值 17,625,163.60 美元。該交易在與證券交易委員會的法律文件中披露，該文件可通過以下方式訪問 此超連結。在其他消息中，執行副總裁安·鮑威爾（Ann Powell）在 2 月 6 日（星期一）的交易中出售了該公司股票的 11,183 股。這些股份以 74.69 美元的平均價格出售，總價值為 835,258.27 美元。出售完成後，執行副總裁現擁有該公司股票的 23,043 股，價值約為 1,721,081.67 美元。該交易在與證券交易委員會的法律文件中披露，該交易可通過以下方式獲得 證券交易所網站。此外，首席執行官喬瓦尼·卡福里奧在 2 月 6 日（星期一）的交易中出售了該企業股票的 240,000 股。這些股票以 74.65 美元的平均價格出售，總交易額為 17,916 萬美元。交易完成後，首席執行官現直接擁有該公司股票的 236,104 股，價值 17,625,163.60 美元。可以找到此次銷售的披露 這裡。企業內部人士擁有公司股票的 0.09%。
Bristol-Myers Squibb Profile
百時美施貴寶檔案
(Get Rating)
(取得評分)
Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
布里斯托爾邁爾斯 Squibb 公司從事生物製藥產品的發現，開發，許可，製造，營銷，分銷和銷售。它提供化學合成的藥物或小分子和產品從稱為生物製劑的生物過程產生.該公司成立於 1933 年 8 月，總部位於紐約州紐約。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze, Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
- Walmart Shares Jump on Evercore Analyst Upgrade
- 獲取有關百時美施貴寶（BMY）的股票新聞網研究報告
- 什麼是黃金 IRA 退休賬戶，它是一項可行的投資嗎？
- 是 Braze, 公司準備火箭更高?
- 穆倫汽車製造交貨；短擠壓成為可能
- 前線可以保持這種勢頭嗎？
- 沃爾瑪股票跳躍在 Evercore 分析師升級
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Get Rating).
想看看還有哪些對沖基金持有 BMY？ 訪問 Holdingschannel.com 以獲取百時美施貴寶（紐約證交所代碼：BMY — 獲得評分）的最新 13 樓文件和內幕交易。
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
接收百時美施貴寶日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收百時美施貴寶及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。